Table 1.
Univariate cox proportional risk analysis for OS.
| Co-Variates | Values | HR | 95% CI | p-Value |
|---|---|---|---|---|
| Age (years) | ≥65 vs. <65 | 1.02 | 0.51–2.03 | 0.951 |
| Sex | Female vs. Male | 1.24 | 0.81–1.89 | 0.313 |
| Setting | Recurrent vs. metastatic | 1.36 | 0.70–2.65 | 0.361 |
| Alcohol consumption | Heavy vs. Light/No | 0.85 | 0.58–1.24 | 0.413 |
| Smoking | Heavy vs. Light/No | 1.02 | 0.45–2.30 | 0.955 |
| Primary site | Oral cavity vs. other | 1.24 | 0.87–1.76 | 0.225 |
| Line of immunotherapy | 2nd+ vs. first | 1.85 | 0.92–3.71 | 0.084 |
| Type of PD (TGKR) | HPD vs. PD | 1.72 | 0.85–3.48 | 0.131 |
| HPD vs. non-HPD | 2.29 | 1.13–4.65 | 0.021 | |
| Type of PD (ΔTGR) | HPD vs. non-HPD | 1.25 | 0.43–3.59 | 0.675 |
| Recurrence (Local) | Present vs. Absent | 1.96 | 0.87–4.03 | 0.065 |
| Recurrence (Regional) | Present vs. Absent | 0.86 | 0.44–1.65 | 0.645 |
| Recurrence (Distant) | Present vs. Absent | 0.59 | 0.28–1.23 | 0.163 |
| Local PD | Present vs. Absent | 2.43 | 1.18–4.97 | 0.015 |
| Systematic PD | Present vs. Absent | 1.41 | 0.65–3.04 | 0.380 |
| LDH | Abnormal vs. normal | 1.090 | 0.55–2.16 | 0.805 |
| ECOG PS | 1 vs. 0 | 2.56 | 0.011 | |
| 2 vs. 0 | 4.26 | 0.009 |
HR: hazard ratio; PD: progressive disease; HPD: hyperprogressive disease; TGKR: tumor growth kinetics ratio; ΔTGR: change in tumor growth rate; LDH: lactate dehydrogenase; ECOG PS: Eastern Cooperative Oncology group performance status. Statistical significance is noted in bold.